Skip to Content
Merck
All Photos(1)

Key Documents

SML3388

Sigma-Aldrich

Vortioxetine hydrobromide

≥98% (HPLC)

Synonym(s):

1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine hydrobromide, Lu AA21004 HBr, Lu AA21004 hydrobromide, Vortioxetine HBr

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H22N2S·HBr
CAS Number:
960203-27-4
Molecular Weight:
379.36
MDL number:
MFCD22383961
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C18H22N2S.BrH/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20;/h3-8,13,19H,9-12H2,1-2H3;1H

InChI key

VNGRUFUIHGGOOM-UHFFFAOYSA-N

Biochem/physiol Actions

Vortioxetine (Lu AA21004) is an orally active, multimodal serotonergic compound with high affinity toward human 5-HT1A (Ki = 15 nM), 5-HT1B (Ki = 33 nM), 5-HT1D (Ki = 54 nM), 5-HT3A (Ki = 3.7 nM), 5-HT7 (Ki = 19 nM), noradrenergic β1 (Ki = 46 nM) receptors, and serotonin (5-HT) transporter (SERT Ki = 1.6 nM). Vortioxetine exhibits in vivo psychotropic efficacy by exerting antagonist activity against 5-HT-1D/3A/7, agonist activity on 5-HT1A, partial agonist activity on 5-HT1B, as well as potent SERT inhibitory activity.

Pictograms

Health hazardEnvironment
GHS08,GHS09

Signal Word

Warning

Hazard Statements

H361d,H373,H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1 - Repr. 2 - STOT RE 2

Target Organs

Kidney

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ashley Wallace et al.
The international journal of neuropsychopharmacology, 17(10), 1695-1706 (2014-05-24)
Current treatments for depression, including serotonin-specific reuptake inhibitors (SSRIs), are only partially effective, with a high incidence of residual symptoms, relapse, and treatment resistance. Loss of cognitive flexibility, a component of depression, is associated with dysregulation of the prefrontal cortex.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service